Mustang Bio Inc (MBIO)

$1.52 +0.05 (3.40%)
Market Cap 6.44M
Revenue (ttm) 0.00
Net Income (ttm) -15.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 74,900
Avg Vol 7,199,262
Day's Range N/A - N/A
Shares Out 4.38M
Stochastic %K 21%
Beta 2.22
Analysts Strong Buy
Price Target $8.00

Company Profile

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 201...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 652 4500
Address:
95 Sawyer Road, Suite 110, Waltham, United States
Goldwave9
Goldwave9 Aug. 8 at 4:41 PM
$MBIO Long way to go. Up. But not in a straight line.
0 · Reply
SEVENXStheGOAT
SEVENXStheGOAT Aug. 8 at 3:15 PM
$MBIO break that 1.73
0 · Reply
Mg_1970
Mg_1970 Aug. 8 at 3:09 PM
$MBIO If it breaks 1.75 it could fly
0 · Reply
Hendo111
Hendo111 Aug. 8 at 2:21 PM
$MBIO
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Aug. 8 at 2:01 PM
$MBIO
1 · Reply
Hendo111
Hendo111 Aug. 7 at 4:07 PM
$CEIN $PHAT $LCTX $MBIO
1 · Reply
Rickyjudd
Rickyjudd Aug. 7 at 1:01 AM
$MBIO good chance to short squeeze I think
0 · Reply
Chasse_patate
Chasse_patate Aug. 6 at 8:01 PM
$MBIO This chart is all you need to know
0 · Reply
Hendo111
Hendo111 Aug. 6 at 1:56 PM
$CEIN $PHAT $CTM $MBIO $LCTX 💚
1 · Reply
Mg_1970
Mg_1970 Aug. 5 at 6:34 PM
$MBIO I bought it around $2 then sold in loss -5% Now I've rebought 1.49 avg 3000 🤞😎 We need volumes buy signal triggered at 1.52
2 · Reply
Latest News on MBIO
Dow Dips 1%; Mustang Bio Shares Spike Higher

Jul 7, 2025, 12:30 PM EDT - 4 weeks ago

Dow Dips 1%; Mustang Bio Shares Spike Higher

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

Jul 7, 2025, 8:30 AM EDT - 4 weeks ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

Mar 5, 2025, 4:15 PM EST - 5 months ago

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

FBIO

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Feb 27, 2025, 4:05 PM EST - 5 months ago

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 11, 2025, 4:10 PM EST - 6 months ago

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mustang Bio Announces Closing of $8 Million Public Offering

Feb 10, 2025, 8:00 AM EST - 6 months ago

Mustang Bio Announces Closing of $8 Million Public Offering

Mustang Bio Announces Pricing of $8 Million Public Offering

Feb 6, 2025, 7:00 AM EST - 6 months ago

Mustang Bio Announces Pricing of $8 Million Public Offering

Mustang Bio Announces Reverse Stock Split

Jan 14, 2025, 8:00 AM EST - 7 months ago

Mustang Bio Announces Reverse Stock Split

Mustang Bio Receives Positive Listing Determination from Nasdaq

Nov 12, 2024, 8:30 AM EST - 9 months ago

Mustang Bio Receives Positive Listing Determination from Nasdaq

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Nov 7, 2024, 8:30 AM EST - 9 months ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Oct 24, 2024, 2:10 PM EDT - 10 months ago

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

ENVB

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 21, 2024, 4:01 PM EDT - 1 year ago

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2024, 8:00 AM EDT - 1 year ago

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Why are Mustang Bio shares (MBIO) up almost 500%?

Jun 18, 2024, 2:52 AM EDT - 1 year ago

Why are Mustang Bio shares (MBIO) up almost 500%?

Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?

Jun 17, 2024, 9:21 AM EDT - 1 year ago

Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

Mustang Bio Announces Closing of $4 Million Public Offering

May 2, 2024, 4:01 PM EDT - 1 year ago

Mustang Bio Announces Closing of $4 Million Public Offering

Mustang Bio Announces Pricing of $4 Million Public Offering

Apr 29, 2024, 8:00 PM EDT - 1 year ago

Mustang Bio Announces Pricing of $4 Million Public Offering

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mar 28, 2024, 9:00 AM EDT - 1 year ago

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Mar 11, 2024, 4:05 PM EDT - 1 year ago

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Mar 7, 2024, 7:30 AM EST - 1 year ago

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Jan 11, 2024, 8:30 AM EST - 1 year ago

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Dec 11, 2023, 8:30 AM EST - 1 year ago

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 14, 2023, 4:05 PM EST - 1 year ago

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Nov 2, 2023, 9:28 AM EDT - 1 year ago

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 30, 2023, 2:15 PM EDT - 1 year ago

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 12:30 PM EDT - 1 year ago

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Oct 26, 2023, 9:00 AM EDT - 1 year ago

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

Sep 7, 2023, 8:15 AM EDT - 2 years ago

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Aug 16, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Aug 14, 2023, 4:05 PM EDT - 2 years ago

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Mustang Bio to Participate in Two August 2023 Investor Conferences

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio to Participate in Two August 2023 Investor Conferences

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

Jul 31, 2023, 8:30 AM EDT - 2 years ago

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

Mustang Bio Announces Participation in Upcoming Scientific Meetings

Jul 6, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces Participation in Upcoming Scientific Meetings

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Jun 15, 2023, 4:01 PM EDT - 2 years ago

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Jun 12, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

May 18, 2023, 8:03 AM EDT - 2 years ago

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 12, 2023, 4:05 PM EDT - 2 years ago

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

May 11, 2023, 4:03 PM EDT - 2 years ago

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Mar 29, 2023, 4:15 PM EDT - 2 years ago

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Mustang Bio to Participate in Cantor's The Future of Oncology Virtual Symposium

Mar 28, 2023, 8:30 AM EDT - 2 years ago

Mustang Bio to Participate in Cantor's The Future of Oncology Virtual Symposium

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

Jan 17, 2023, 8:15 AM EST - 2 years ago

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Dec 19, 2022, 8:30 AM EST - 2 years ago

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Nov 14, 2022, 4:05 PM EST - 2 years ago

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

Oct 27, 2022, 8:00 AM EDT - 3 years ago

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Oct 6, 2022, 8:30 AM EDT - 3 years ago

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio: This Horse May Gallop Still

Sep 23, 2022, 4:55 PM EDT - 3 years ago

Mustang Bio: This Horse May Gallop Still

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Aug 11, 2022, 4:05 PM EDT - 3 years ago

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Goldwave9
Goldwave9 Aug. 8 at 4:41 PM
$MBIO Long way to go. Up. But not in a straight line.
0 · Reply
SEVENXStheGOAT
SEVENXStheGOAT Aug. 8 at 3:15 PM
$MBIO break that 1.73
0 · Reply
Mg_1970
Mg_1970 Aug. 8 at 3:09 PM
$MBIO If it breaks 1.75 it could fly
0 · Reply
Hendo111
Hendo111 Aug. 8 at 2:21 PM
$MBIO
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Aug. 8 at 2:01 PM
$MBIO
1 · Reply
Hendo111
Hendo111 Aug. 7 at 4:07 PM
$CEIN $PHAT $LCTX $MBIO
1 · Reply
Rickyjudd
Rickyjudd Aug. 7 at 1:01 AM
$MBIO good chance to short squeeze I think
0 · Reply
Chasse_patate
Chasse_patate Aug. 6 at 8:01 PM
$MBIO This chart is all you need to know
0 · Reply
Hendo111
Hendo111 Aug. 6 at 1:56 PM
$CEIN $PHAT $CTM $MBIO $LCTX 💚
1 · Reply
Mg_1970
Mg_1970 Aug. 5 at 6:34 PM
$MBIO I bought it around $2 then sold in loss -5% Now I've rebought 1.49 avg 3000 🤞😎 We need volumes buy signal triggered at 1.52
2 · Reply
SEVENXStheGOAT
SEVENXStheGOAT Aug. 5 at 5:02 PM
$MBIO curling
0 · Reply
bobbydoles
bobbydoles Aug. 4 at 9:15 PM
$MBIO been buying daily under $ last spike was what $7...?
0 · Reply
QuantNut
QuantNut Aug. 4 at 5:48 PM
$MBIO ummm…. You’re a moron cause I’ve stated where this is heading multiple times since $6. Stay stupid buddy 😉😉😉
1 · Reply
QuantNut
QuantNut Aug. 4 at 5:00 PM
$MBIO lol prove it.
2 · Reply
Zellchair
Zellchair Aug. 3 at 1:20 PM
$FBIO $DERM $CKPT $MBIO Fortress Biotech Pref FBIOP (special situation) - Substack 7-8 Part 7 - Fortress Biotech FBIOP - AstraZeneca's Q2 gives renewed real hope for CAEL-101 plus more news regarding Triplex, Dotinurad, UNLOCXYT & Journey Medical https://zellchair.substack.com/p/fortress-biotech-fbiop-astrazenecas Part 8 - Fortress Biotech – New major revelations about Crystalys (Dotinurad), UNLOXCYT launch & Triplex “competitors” Q1 sales https://zellchair.substack.com/p/fortress-biotech-new-major-revelations $XBI
1 · Reply
Goldwave9
Goldwave9 Aug. 1 at 5:42 PM
$MBIO Easy double, toil and trouble
1 · Reply
mak82
mak82 Aug. 1 at 4:00 PM
$MBIO why they are not throwing any guideline after FDA approved? No marketing policies or buyout. Everyday doing dilution
0 · Reply
SMM82
SMM82 Aug. 1 at 2:12 PM
$MBIO If nothing else, this one is consistent.
0 · Reply
2pumps1dump
2pumps1dump Aug. 1 at 10:19 AM
$MBIO US based!
0 · Reply
SMM82
SMM82 Jul. 31 at 1:15 PM
$MBIO Interesting news today from $ONC and their Prime designation for potential treatment of Waldenstroms Macroglobulinemia (WM). Some Similarities with Mustang’s MB-106 program upon quick glance…
0 · Reply
StockMasterCash
StockMasterCash Jul. 31 at 12:25 PM
$MBIO some volume , anyone know why?
1 · Reply
SMM82
SMM82 Jul. 29 at 9:28 PM
$MBIO Hard to touch this one until we see the next 10K report or filing showing their outstanding share count. Guessing plenty of dilution the past few weeks. This was trading around $4-5m market cap before the pop. Expect it to head back to that level, even with the shares diluted.
1 · Reply